In patients with NSCLC, NSE has been suggested as a prognostic marker [15] and some studies have presented an association between increased NSE and shorter survival in EGFR-mutated NSCLC treated with tyrosine kinase inhibitors (TKI ́s) [16, 17]. The gene discussed is ENO2; the disease is non-small cell lung carcinoma.